[Echography and guided aspiration needle biopsy in the diagnosis of the surgical patient]. / L'ecografia e l'agobiopsia aspirativa mirata nell'iter diagnostico del paziente chirurgico.

Reference is made to the literature and personal experience for the view that the progress reached in diagnosis with echography combined with oriented needle biopsy makes it possible to accelerate the course of diagnosis to a considerable degree in 90% of surgical cases.

Clinical pharmacokinetics of cefotaxime and penetration in sputum, bone, and prostatic tissue.

Cefotaxime is a new powerful methoxycephalosporin with a broad anti-microbial spectrum, suitable for parenteral administration. In the present study, the concentrations of cefotaxime in serum and in bronchial secretion were determined after intramuscular injection of 1 gm every eight hours for seven days. Subjects were patients suffering from an exacerbation of chronic bronchitis. Serum levels versus time curve were interpreted in terms of a one-compartment open model. Pharmacokinetic parameters after single and multiple doses were investigated. No evidence of significant accumulation was found. Furthermore, a type of in vivo rate of killing with cefotaxime was investigated by evaluating the decrease in the number of colonies in bronchial mucus cultures daily for seven days. In two groups of volunteers who had to undergo surgery, bone and prostatic concentrations of cefotaxime were determined and correlated with serum levels.

[Treatment of prostatic hypertrophy with synthetic progestational hormones]. / Osservazioni cliniche sul trattamento dell'ipertrofia prostatica con progestativi di sintesi.

PIP: Prostate hypertrophy is common to about 75% of men over 60 years of age; surgical treatment is not always possible due to the clinical conditions of patients, or to their advanced age. 40 patients aged 50-88 affected with prostate hypertrophy in various degrees of severity, were treated with MAP (6-alpha-methyl-17-al pha-acetoxyprogesterone) by intramuscular administration of 200 mg MAP in 4 daily doses for 10 days, followed by 100 mg in 2 daily doses for another 10 days, and again 50 mg in 1 daily dose for the next 10 days. Patients were followed closely: urographic and cystographic examinations were done at beginning and at end of treatment. In most cases all clinical symptomatology was notably improved, with a great reduction in the number of urination problems; in some cases there was also a reduction in the volume of prostate hypertrophy; laboratory tests showed a marked improvement in all renal functions.^ieng